A combination of a compound according to Formula: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Xis O; Y is a 5-membered or a 6-membered heteroaryl; R 1 and R 2 independently are aryl or heteroaryl; R 3a, R 3b, R 4a and R 4b independently are H, halogen, CN, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, (C 2 -C 8)alkenyl, (C 2 -C 8)alkynyl, OR 9, NHR 9, NR 9 R 9, [(C 1 -C 8)alkylene]OR 9, [(C 1 -C 8)alkylene]NHR 9, [(C 1 -C 8)alkylene]NR 9 R 9, C R 8, C NHR 9, C NR 9 R 9, C [(C 1 -C 8)alkylene]NHR 9, C [(C 1 -C 8)alkylene]NR 9 R 9, CO 2 R 9, C NHR 9, C NR 9 R 9, SR 9, S R 9, SO 2 R 9, SO 2 NHR 9, SO 2 NR 9 R 9, NH R 8, NR 9 R 8, NH NHR 9, NH NR 9 R 9, NR 9 NHR 9, NR 9 NR 9 R 9, P (OR 9), P (OR 9) (OR 9), aryl, heteroaryl, cycloalkyl or heterocyclyl; R 3a and R 3b, and R 4a and R 4b independently combine to form oxo or alkenyl, or a cycloalkyl or heterocyclyl ring; or R 3a and R 4a, R 3b and R 4b or R 4a and R 5 together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl ring; or R 2 and R 3a together with the carbon atom to which they are attached form a bicvclic ring system, R 5 is H. halogen. OH. CN. N 3. SR 9. (C 1 -C 8 lalkyl. (C 1 -C 8)haloalkyl. O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, (C 2 -C 8)alkynyl, NHC (C 1 -C 8)alkyl or heteroaryl; R 8 is H, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, cycloalkyl, O(cycloalkyl), heterocyclyl, O(heterocyclyl), aryl, O(aryl), heteroaryl or O(heteroaryl); and R 9 is H, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, cycloalkyl, heterocyclyl, [(C 1 -C 8)alkylene] heterocyclyl, aryl, [(C 1 -C 8)alkylene] aryl or heteroaryl; wherein the two R 9 's together with the nitrogen atom to which they are attached of NR 9 R 9, [(C 1 -C 8)alkylene]NR 9 R 9, C NR 9 R 9, C [(C 1 -C 8)alkylene]NR 9 R 9, C NR 9 R 9, SO 2 NR 9 R 9, NH NR 9 R 9 or NR 9 NR 9 R 9, optionally form a heterocyclyl ring; wherein any alkyl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl or aryl is optionally substituted with 1, 2, or 3 groups selected from OH, CN, SH, SO 2 NH 2, SO 2 (C 1 -C 4)alkyl, SO 2 NH(C 1 -C 4)alkyl, halogen, NH 2, NH(C 1 -C 4)alkyl, N[(C 1 -C 4)alkyl] 2, C NH 2, COOH, COOMe, acetyl, (C 1 -C 8)alkyl, O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, (C 2 -C 8)alkenyl, (C 2 -C 8)alkynyl, haloalkyl, and thioalkyl; or wherein any alkyl, cycloalkyl or heterocyclyl is optionally substituted with oxo; and a chemotherapeutic agent; for use in a method of treating an eIF4A dependent condition in a mammal in need thereof. Xis O; Y is a 5-membered or a 6-membered heteroaryl; R 1 and R 2 independently are aryl or heteroaryl; R 3a, R 3b, R 4a and R 4b independently are H, halogen, CN, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, (C 2 -C 8)alkenyl, (C 2 -C 8)alkynyl, OR 9, NHR 9, NR 9 R 9, [(C 1 -C 8)alkylene]OR 9, [(C 1 -C 8)alkylene]NHR 9, [(C 1 -C 8)alkylene]NR 9 R 9, C R 8, C NHR 9, C NR 9 R 9, C [(C 1 -C 8)alkylene]NHR 9, C [(C 1 -C 8)alkylene]NR 9 R 9, CO 2 R 9, C NHR 9, C NR 9 R 9, SR 9, S R 9, SO 2 R 9, SO 2 NHR 9, SO 2 NR 9 R 9, NH R 8, NR 9 R 8, NH NHR 9, NH NR 9 R 9, NR 9 NHR 9, NR 9 NR 9 R 9, P (OR 9), P (OR 9) (OR 9), aryl, heteroaryl, cycloalkyl or heterocyclyl; R 3a and R 3b, and R 4a and R 4b independently combine to form oxo or alkenyl, or a cycloalkyl or heterocyclyl ring; or R 3a and R 4a, R 3b and R 4b or R 4a and R 5 together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl ring; or R 2 and R 3a together with the carbon atom to which they are attached form a bicvclic ring system, R 5 is H. halogen. OH. CN. N 3. SR 9. (C 1 -C 8 lalkyl. (C 1 -C 8)haloalkyl. O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, (C 2 -C 8)alkynyl, NHC (C 1 -C 8)alkyl or heteroaryl; R 8 is H, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, cycloalkyl, O(cycloalkyl), heterocyclyl, O(heterocyclyl), aryl, O(aryl), heteroaryl or O(heteroaryl); and R 9 is H, (C 1 -C 8)alkyl, (C 1 -C 8)haloalkyl, cycloalkyl, heterocyclyl, [(C 1 -C 8)alkylene] heterocyclyl, aryl, [(C 1 -C 8)alkylene] aryl or heteroaryl; wherein the two R 9 's together with the nitrogen atom to which they are attached of NR 9 R 9, [(C 1 -C 8)alkylene]NR 9 R 9, C NR 9 R 9, C [(C 1 -C 8)alkylene]NR 9 R 9, C NR 9 R 9, SO 2 NR 9 R 9, NH NR 9 R 9 or NR 9 NR 9 R 9, optionally form a heterocyclyl ring; wherein any alkyl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl or aryl is optionally substituted with 1, 2, or 3 groups selected from OH, CN, SH, SO 2 NH 2, SO 2 (C 1 -C 4)alkyl, SO 2 NH(C 1 -C 4)alkyl, halogen, NH 2, NH(C 1 -C 4)alkyl, N[(C 1 -C 4)alkyl] 2, C NH 2, COOH, COOMe, acetyl, (C 1 -C 8)alkyl, O(C 1 -C 8)alkyl, O(C 1 -C 8)haloalkyl, (C 2 -C 8)alkenyl, (C 2 -C 8)alkynyl, haloalkyl, and thioalkyl; or wherein any alkyl, cycloalkyl or heterocyclyl is optionally substituted with oxo; and a chemotherapeutic agent; for use in a method of treating an eIF4A dependent condition in a mammal in need thereof.